A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis

Myasthenia Gravis Clinical Trial

Official title:

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04224506
• Other study ID #: PRG-039
• Status: Recruiting
• Start date: March 2, 2020
• Est. completion date: July 2023

Study information

• Verified date: September 2021
• Source: ProgenaBiome
• Contact: Sabine Hazan, MD
• Phone: 18053390549
• Email: drsabinehazan[@]progenabiome.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

Description:

The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to Myasthenia Gravis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: July 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study

a. May be signed by parent or legal guardian in the case of minor or adult unable to provide consent

2. Male or female of all ages.

3. Diagnosis of Myasthenia Gravis by a physician

Exclusion Criteria:

1. Refusal to sign informed consent form

2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.

3. Postoperative stoma, ostomy, or ileoanal pouch

4. Participation in any experimental drug protocol within the past 12 weeks

5. Treatment with total parenteral nutrition

Related Conditions & MeSH terms

• Muscle Weakness
• Myasthenia Gravis
• Myasthenia Gravis, Generalized

Intervention

Other:
• No intervention
There is no intervention for this study.

Locations

Country	Name	City	State
United States	ProgenaBiome	Ventura	California

Sponsors (1)

Lead Sponsor	Collaborator
ProgenaBiome

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing	Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be categorized with Myasthenia Gravis.	Three years